Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma

Cancer

Volumn 107, Issue 3, 2006, Pages 497-505

  Tannir, Nizar ^a   Jonasch, Eric ^a   Pagliaro, Lance C ^a   Mathew, Paul ^a   Siefker Radtke, Arlene ^a   Rhines, Laurence ^a   Lin, Patrick ^a   Tibbs, Rita ^a   Do, Kim Anh ^a   Lin, Sue Hwa ^a   Tu, Shi Ming ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bisphosphonates; Bone metastasis; Renal cell carcinoma; Zoledronate

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; ALPHA INTERFERON; AMINO TERMINAL TELOPEPTIDE; CAPECITABINE; CP 675206; DEOXYPYRIDINOLINE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2; LAXATIVE; MONOCLONAL ANTIBODY; NARCOTIC AGENT; THALIDOMIDE; UNCLASSIFIED DRUG; WARFARIN; ZOLEDRONIC ACID;

ADRENAL METASTASIS; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ARTIFICIAL EMBOLISM; BONE METASTASIS; CALCIFICATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EVALUATION; FATIGUE; FEMALE; FEVER; HEART INFARCTION; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; KIDNEY FAILURE; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA; OSSIFICATION; OSTEOLYSIS; PAIN; PANCREAS CANCER; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RASH; SENSORY NEUROPATHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INTERFERON TYPE II; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 33746277238     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22038     Document Type: Article

References (29)

1. Swanson DA, Orovan WL, Johnson DE, Giacco G. Osseous metastases secondary to renal cell carcinoma. Urology. 1981;18:556-561.
2. Nielsen OS, Monro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509-524.
3. Atkins MB, Regan M, McDermott D. Update on the role of interleukin-2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res. 2004;10:63425-63465.
4. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
5. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
6. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [ Abstract LBA4510]. Proc Am Soc Clin Oncol. (ASCO) 2005.
7. Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trial of SU-11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma [Abstract 4508]. Proc Am Soc Clin Oncol. (ASCO) 2005.
8. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer [Abstract 4509]. Proc Am Soc Clin Oncol. (ASCO) 2005.
9. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998;12:220-229.
10. Shipman CM, Croucher PI, Russell GG, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58:5294-5297.
11. Savage AD, Belson DJ, Vescio RA, et al. Pamidronate reduces IL-6 production by bone marrow stroma from myeloma patients. Blood. 1996;88:105a.
12. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962-969.
13. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885-1892.
14. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31:213-221.
15. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-386.
16. Eisen TG. Thalidomide in solid tumors: the London experience. Oncology. 2000;14(Suppl 13):17-20.
17. Daliani D, Papandreou CN, Thall PF, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer. 2002;95:758-765.
18. Takayanagi H, Ogasawara K, Hida S, et al. T-cell mediated regulation of osteoclastogenesis by signalling crosstalk between RANKL and IFN-γ. Nature. 2000;408;600-604.
19. Gleave ME, Elhilali M, Radet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma. N Engl J Med. 1998;338:1265-1271.
20. Aulitzky W, Gastl G, Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with biologically active dose of recombinant interferon gamma. J Clin Oncol. 1989;7:1875-1884.
21. Ellerhorst JA, Kilbourn RG, Amato RJ, et al. Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma. J Urol. 1994;152:841-845.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-461.
23. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.
24. Coleman RE. Evaluation of bone disease in breast cancer. Breast. 1994;3:73-78.
25. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925-4935.
26. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000;88:2919-2926.
27. Izumi M, Nakanishi Y, Takayama K, et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer. 2001;91:1487-1493.
28. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998;34:2021-2026.
29. Vinholes J, Coleman R, Lacombe D, et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. Br J Cancer. 1999;80:221-228.